$THC

FISHER RICHARD W sold (to issuer) $86K of THC

FISHER RICHARD W sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · FISHER RICHARD W
Published May 27, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure provides ownership-change information but does not include any company-specific catalyst; trading impact is likely limited unless it signals a broader insider behavior shift.

02

Market read

A director’s sale to the issuer is typically low-signal for fundamentals, suggesting limited trading edge absent corroborating news or insider-trend context.

03

What to watch

Check for clustering of insider sales across multiple filings and whether other directors/officers are also trimming around the same dates; that pattern would matter more than this single Form 4.

Relevance 6/10Timing: Immediate (same-day/next-session digestion of Form 4), but typically not a driver of follow-through.

Background

The filing is an SEC Form 4 insider transaction disclosure for Tenet Healthcare director Richard W. Fisher.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Richard W. Fisher sold 493 shares to the issuer on 2026-05-22 at $173.78/share, per SEC Form 4.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-noise unless part of a broader insider trend.

Evidence & confidence

Form 4 details a small director sale to issuer under code D, with no 10b5-1 plan and no accompanying company news (earnings, guidance, deals, litigation).

Market effects

Minimal; single insider Form 4 without company fundamentals rarely resets sector expectations.

None indicated.

None indicated.

Counterpoint

Because the transaction is a sale to the issuer (often buyback/plan mechanics), it may not reflect bearish views on Tenet’s prospects.

Key entities

  • TENET HEALTHCARE CORP

    Subject of the Form 4 insider transaction; director sold shares to the issuer.

  • FISHER RICHARD W

    Tenet Healthcare director who reported the sale.

Related articles

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.

$THCHighAI 9/10

Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook

Tenet Healthcare (THC) reported Q2 2026 adjusted EPS of $6.12, 50% above the Zacks Consensus, with net operating revenues up 6.8% to $5.63B. Adjusted net income rose 39.3% to $514M. The company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and authorized a $2B share repurchase increase.

$THCMedAI 8/10

Why Tenet Healthcare Stock Is Soaring Today

Tenet Healthcare (THC) shares rose after the company reported fiscal Q2 results and raised 2026 guidance. For the quarter ended in June, revenue was $5.63B and adjusted EPS was $6.12, both above year-ago figures and analyst estimates ($5.43B revenue, $4.26 EPS). 2026 revenue guidance increased to $21.9B-$22.5B and adjusted EBITDA to $4.83B-$5.03B.